1. Home
  2. AEI vs CRVO Comparison

AEI vs CRVO Comparison

Compare AEI & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alset Inc. (TX)

AEI

Alset Inc. (TX)

HOLD

Current Price

$2.69

Market Cap

91.4M

Sector

Real Estate

ML Signal

HOLD

Logo CervoMed Inc.

CRVO

CervoMed Inc.

HOLD

Current Price

$8.34

Market Cap

89.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AEI
CRVO
Founded
2014
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Building operators
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
91.4M
89.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
AEI
CRVO
Price
$2.69
$8.34
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$21.50
AVG Volume (30 Days)
37.1K
79.7K
Earning Date
11-14-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$12,108,028.00
$6,159,786.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.70
$1.80
52 Week High
$4.55
$16.94

Technical Indicators

Market Signals
Indicator
AEI
CRVO
Relative Strength Index (RSI) 47.78 48.39
Support Level $2.68 $8.13
Resistance Level $3.45 $9.22
Average True Range (ATR) 0.35 0.61
MACD 0.02 -0.12
Stochastic Oscillator 26.74 23.41

Price Performance

Historical Comparison
AEI
CRVO

About AEI Alset Inc. (TX)

Alset Inc is a diversified holding company engaged through its subsidiaries in the development of EHome communities and other real estate, financial services, digital transformation technologies, biohealth activities, and consumer products with operations in the United States, Singapore, Hong Kong, Australia, and South Korea. The Company operates in four business segments: real estate, digital transformation technology, Biohealth, and other business activities, and it derives a majority of its revenue from the Real Estate segment.

About CRVO CervoMed Inc.

CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.

Share on Social Networks: